Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Nucl Med ; 64(9): 1392-1398, 2023 09.
Article in English | MEDLINE | ID: mdl-37385670

ABSTRACT

223Ra, a targeted α-therapy, is approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have bone metastases. In the phase 3 ALSYMPCA study, 223Ra prolonged survival and improved quality of life versus placebo. Our real-world study, PARABO, investigated pain and bone pain-related quality of life in patients with mCRPC and symptomatic bone metastases receiving 223Ra in clinical practice. Methods: PARABO was a prospective, observational, noninterventional single-arm study conducted in nuclear medicine centers across Germany (NCT02398526). The primary endpoint was a clinically meaningful pain response (≥2-point improvement from baseline for the worst-pain item score in the Brief Pain Inventory-Short Form). Results: The analysis included 354 patients, who received a median of 6 223Ra injections (range, 1-6). Sixty-seven percent (236/354) received 5-6 injections, and 33% (118/354) received 1-4 injections. Of 216 patients with a baseline worst-pain score of more than 1, 59% (128) had a clinically meaningful pain response during treatment. Corresponding rates were 67% (range, 98/146) with 5-6 223Ra injections versus 43% (range, 30/70) with 1-4 injections, 60% (range, 60/100) in patients with no more than 20 lesions versus 59% (range, 65/111) in those with more than 20 lesions, and 65% (range, 69/106) in patients without prior or concomitant opioid use versus 54% (range, 59/110) in those with prior or concomitant opioid use. Mean subscale scores (pain severity and pain interference) on the Brief Pain Inventory-Short Form improved during treatment. Conclusion: 223Ra reduced pain in patients with mCRPC and symptomatic bone metastases, particularly in patients who received 5-6 injections. The extent of metastatic disease did not impact pain response.


Subject(s)
Bone Neoplasms , Prostatic Neoplasms, Castration-Resistant , Radium , Humans , Male , Analgesics, Opioid/therapeutic use , Bone Neoplasms/secondary , Pain/complications , Prospective Studies , Prostatic Neoplasms, Castration-Resistant/pathology , Quality of Life , Radium/therapeutic use
2.
Chirurg ; 92(1): 34-39, 2021 Jan.
Article in German | MEDLINE | ID: mdl-32968827

ABSTRACT

Hot and hyperfunctioning thyroid gland nodules are currently treated primarily by radioiodine or surgical resection. In recent years local thermal ablation as an alternative therapeutic modality is increasingly recommended. This article reports the case of a patient with a hot thyroid nodule, which was resected and turned out to be follicular thyroid cancer. In this context it appears to be necessary to critically question thermal ablation as an alternative treatment option for thyroid nodules, particularly since the current recommendations are weak with low or even very low evidence. Radioiodine or surgery remains the first-line treatment for hot and hyperfunctioning thyroid nodules but malignancy in a hot thyroid nodule also needs to be considered.


Subject(s)
Adenocarcinoma, Follicular , Thyroid Neoplasms , Thyroid Nodule , Adenocarcinoma, Follicular/surgery , Humans , Iodine Radioisotopes , Thyroid Neoplasms/surgery , Thyroid Nodule/surgery
3.
Clin Nucl Med ; 36(10): 841-7, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21892031

ABSTRACT

PURPOSE: (1) To investigate the diagnostic value of some O-(2-[F]fluoroethyl)-L-tyrosine (F-18 FET) indices derived from the dynamic acquisition to differentiate low-grade gliomas from high-grade; (2) to analyze the course of tumor time-activity curves (TACs); and (3) to calculate the individual probability of a high-grade glioma using the logistic regression. METHODS: Seventeen low-grade (WHO I-II) and 15 high-grade (WHO III-IV) gliomas were studied with dynamic F-18 FET PET. Regions of interests were drawn over the tumor and contralateral brain, and TACs were analyzed. We considered early standardized uptake value (SUV), middle SUV, late SUV, early-to-middle SUV tumor ratio, early-to-late SUV tumor ratio; time to peak (Tpeak), in minutes, from the beginning of the dynamic acquisition up to the maximum SUV of the tumor; and SoD (sum of the frame-to-frame differences). To assess the individual probability of high-grade, logistic regression was also used. RESULTS: High-grade gliomas showed significantly (P < 0.0001) higher values when compared with low-grade gliomas in early SUV, early-to-middle ratio, early-to-late ratio, Tpeak, and SoD. For the grading of gliomas, the best indices were early-to-middle ratio and Tpeak providing a diagnostic accuracy of 94%. TACs analysis provided an 87% diagnostic accuracy. For individual high-grade diagnosis, the logistic regression provided 93% sensitivity, 100% specificity, and 97% accuracy. CONCLUSION: Early-to-middle SUV tumor ratio and Tpeak were the best indices for assessing the grading of gliomas. Since early-to-middle ratio derives from the first 35 minutes of the dynamic acquisition, the PET study could last half an hour instead of 1 hour. By logistic regression, it is possible to assess the individual probability of high-grade, useful for prognosis and treatment.


Subject(s)
Brain Neoplasms/diagnostic imaging , Brain Neoplasms/pathology , Glioma/diagnostic imaging , Glioma/pathology , Positron-Emission Tomography , Tyrosine/analogs & derivatives , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Neoplasm Grading , Time Factors , Tyrosine/pharmacokinetics , Young Adult
4.
Recent Results Cancer Res ; 162: 195-202, 2003.
Article in English | MEDLINE | ID: mdl-12790335

ABSTRACT

A prospective analysis was performed in 124 non-small cell lung cancer patients to determine the role of F-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) for molecular (metabolic) staging (n=63), therapy monitoring after induction-chemotherapy (n=34), and conformal radiation treatment planning (n=27). Staging by FDG-PET was significantly more accurate than CT (p<0.001) and changed therapeutic management in 52% of all patients. After induction-chemotherapy, patients with complete metabolic remission histologically did not show vital tumor cells in contrast to patients with metabolic partial remission or progressive disease. Metabolic radiation treatment planning by PET led to smaller planning target volumes (PTVs) for radiation therapy (between 3% and 21% in 25/27 patients), resulting in a reduction of dose exposure to healthy tissue. In two patients, PET-PTV was larger than CT-based PTV, since PET detected lymph node metastases smaller than 1 cm. FDG-PET provides clinically important information; changes therapeutic management, can predict noninvasively effectiveness of chemotherapy, and may lead to better tumor control with less radiation-induced toxicity.


Subject(s)
Neoplasms/radiotherapy , Radiotherapy Planning, Computer-Assisted/methods , Tomography, Emission-Computed/methods , Disease Progression , Female , Humans , Male , Neoplasm Staging/methods , Prospective Studies , Radiotherapy, Conformal/methods , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...